Literature DB >> 9589674

Increased pulsatile, but not basal, growth hormone secretion rates and plasma insulin-like growth factor I levels during the periovulatory interval in normal women.

P Ovesen1, N Vahl, S Fisker, J D Veldhuis, J S Christiansen, J O Jørgensen.   

Abstract

The secretion of GH changes during the menstrual cycle, exhibiting high levels during the periovulatory phase (PO). Previous studies have not investigated whether this difference in GH status is due to increased secretion or reduced clearance of pituitary GH and amplified pulsatile vs. basal GH secretion. It is also unclear whether the PO phase is accompanied by changes in circulating insulin-like growth factor I (IGF-I). In this study we investigated the 24-h GH release patterns in the early follicular (EF) vs. the periovulatory menstrual phase in the same individuals. Ten young (aged 24-34 yr) healthy women with regular menses were studied with deconvolution analysis of GH profiles obtained by blood sampling every 20 min for 24 h, followed by an arginine stimulation test. A high sensitivity immunofluorometric GH assay was used. All women were studied in both the EF and PO phases in random order. There were no differences in the basal GH secretion rate or GH half-life during the two phases. The number of GH secretory bursts identified during the 24-h sampling period was significantly increased during the PO (13.3 +/- 0.5) compared to the EF (10.3 +/- 0.6) phase (P = 0.002); conversely, the mean interburst interval was shorter in the PO (107 +/- 5 min) than in the EF (134 +/- 8 min) phase (P = 0.004). There was no difference in GH pulse mass (P = 0.13) or amplitude (P = 0.21) between the two phases. The pulsatile GH production rate (milligrams per L/24 h) was significantly elevated during the PO (61 +/- 6) compared to that during the EF (37 +/- 8; P = 0.004). Increased total GH pulse area was confirmed by Cluster analysis (P = 0.027). Furthermore, the 24-h mean serum GH concentration was significantly increased in the PO (1.4 +/- 0.1 mg/L) vs. that in the EF (0.9 +/- 0.1 mg/L; P = 0.002). There was a positive correlation between estradiol (E2) and GH secretory pulse amplitude, frequency, and mean 24-h serum GH concentration in the PO cycle phase, indicating E2 to be a major statistical determinant of GH secretion. Serum GH increased significantly after arginine infusion in both phases (P < 0.001), whereas there was no difference between the two cycle phases (P = 0.20). Serum IGF-I levels were increased during the PO phase (253 +/- 20 mg/L) compared to those during the EF phase (210 +/- 16 mg/L; P = 0.03), whereas serum IGF-binding protein-3, IGF-II, and GH-binding protein were similar during the two phases. This study unequivocally documents elevated GH levels during the PO phase of the menstrual cycle, mediated by increased GH production rate and burst frequency. The concomitant increase in serum IGF-I suggests a central stimulation of the GH-IGF-I axis, which may be mediated by endogenous E2 levels.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9589674     DOI: 10.1210/jcem.83.5.4761

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  29 in total

1.  Determinants of IGF1 and GH across the weight spectrum: from anorexia nervosa to obesity.

Authors:  D J Brick; A V Gerweck; E Meenaghan; E A Lawson; M Misra; P Fazeli; W Johnson; A Klibanski; K K Miller
Journal:  Eur J Endocrinol       Date:  2010-05-25       Impact factor: 6.664

2.  Dehydroepiandrosterone restoration of growth hormone gene expression in aging female rats, in vivo and in vitro: evidence for actions via estrogen receptors.

Authors:  Mary Iruthayanathan; Yi-Hong Zhou; Gwen V Childs
Journal:  Endocrinology       Date:  2005-09-08       Impact factor: 4.736

3.  Bipotential effects of estrogen on growth hormone synthesis and storage in vitro.

Authors:  Gwen V Childs; Mary Iruthayanathan; Noor Akhter; Geda Unabia; Brandy Whitehead-Johnson
Journal:  Endocrinology       Date:  2004-12-23       Impact factor: 4.736

Review 4.  Estrogen mediated cross talk between the ovary and pituitary somatotrope. Pre-ovulatory support for reproductive activity.

Authors:  Gwen V Childs; Mary Iruthayanathan; Noor Akhter; Brandy W Johnson
Journal:  Mol Cell Endocrinol       Date:  2006-01-27       Impact factor: 4.102

Review 5.  Interactive regulation of postmenopausal growth hormone insulin-like growth factor axis by estrogen and growth hormone-releasing peptide-2.

Authors:  J D Veldhuis; W S Evans; C Y Bowers; S Anderson
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

6.  Regulation of basal, pulsatile, and entropic (patterned) modes of GH secretion in a putatively low-somatostatin milieu in women.

Authors:  Johannes D Veldhuis; Susan A Hudson; Joy N Bailey; Dana Erickson
Journal:  Am J Physiol Endocrinol Metab       Date:  2009-06-02       Impact factor: 4.310

7.  Aromatized Estrogens Amplify Nocturnal Growth Hormone Secretion in Testosterone-Replaced Older Hypogonadal Men.

Authors:  Ferdinand Roelfsema; Rebecca J Yang; Paul Y Takahashi; Dana Erickson; Cyril Y Bowers; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2018-12-01       Impact factor: 5.958

8.  Both estrogen receptor α and β stimulate pituitary GH gene expression.

Authors:  Dimiter Avtanski; Horacio J Novaira; Sheng Wu; Christopher J Romero; Rhonda Kineman; Raul M Luque; Fredric Wondisford; Sally Radovick
Journal:  Mol Endocrinol       Date:  2013-01-01

9.  Menopausal status influences the relationship between serum ghrelin levels and fat mass in healthy women.

Authors:  I Iwamoto; N Yoshimitsu; T Fujino; T Douchi
Journal:  J Endocrinol Invest       Date:  2005-05       Impact factor: 4.256

10.  Subchronic exposure to phytoestrogens alone and in combination with diethylstilbestrol - pituitary tumor induction in Fischer 344 rats.

Authors:  Yow-Jiun Jeng; Mikhail Kochukov; Dhananjaya Nauduri; Bhupendra S Kaphalia; Cheryl S Watson
Journal:  Nutr Metab (Lond)       Date:  2010-05-10       Impact factor: 4.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.